<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02502318</url>
  </required_header>
  <id_info>
    <org_study_id>BERNARD PRME 2014</org_study_id>
    <nct_id>NCT02502318</nct_id>
  </id_info>
  <brief_title>Medicoeconomic Evaluation of Two Surgical Techniques for Lobectomy in the Lung Cancer</brief_title>
  <acronym>LungSco01</acronym>
  <official_title>Medicoeconomic Analysis of Lobectomy Using Thoracoscopy vs Thoracotomy for Lung Cancer: a Multicentric Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      This is a national study that involves the participation of 600 lung cancer patients&#xD;
      indicated that treatment is ablation of the pulmonary lobe. This technique is called&#xD;
      lobectomy.&#xD;
&#xD;
      Lobectomy may be performed in two different ways:&#xD;
&#xD;
        -  Thoracotomy, which is the first reference approach and that is to make a large incision&#xD;
           in the chest to pass between the ribs and spread the order to ablate the lobe.&#xD;
&#xD;
        -  By video-thoracoscopy, which is a new surgical approach consisting in practice several&#xD;
           small incisions in the chest wall to allow the introduction of a camera and special&#xD;
           instruments to ablate the lobe.&#xD;
&#xD;
      The mini-invasive nature of video-thoracoscopy has a positive impact on postoperative&#xD;
      expectoration and ventilation. As a result, the incidence of postoperative respiratory&#xD;
      complications including atelectasis, pneumonia and Acute Respiratory Distress Syndrome (ARDS)&#xD;
      is reduced. These respiratory complications are responsible for prolonged stays in Intensive&#xD;
      Care Unit (ICU) and overall hospitalisation. It also has an impact on recovery and quality of&#xD;
      life when patients return home. The reduction in the incidence of complications should&#xD;
      counterbalance the additional cost of video-thoracoscopy.&#xD;
&#xD;
      This study aims to evaluate the effectiveness of these two techniques in relation to the&#xD;
      quality of life and the costs they generate.&#xD;
&#xD;
      Patients who agree to participate in the study were assigned to one or other of these groups&#xD;
      (technical thoracotomy or video-thoracoscopy technique) by lot.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 29, 2015</start_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The postoperative respiratory complications</measure>
    <time_frame>30 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>An incremental cost-utility ratio associated with the use of Video-Assisted Thoracic Surgery when compared with thoracotomy evaluated using the quality of life questionnary EQ-5D</measure>
    <time_frame>3 months after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lobectomy</condition>
  <arm_group>
    <arm_group_label>Lobectomy using video-thoracoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lobectomy using thoracotomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Video-thoracoscopy</intervention_name>
    <arm_group_label>Lobectomy using video-thoracoscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thoracotomy</intervention_name>
    <arm_group_label>Lobectomy using thoracotomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have given their consent&#xD;
&#xD;
          -  Any patient with proven or suspected lung cancer treated by lobectomy.&#xD;
&#xD;
          -  Patients with a negative mediastinoscopy or negative &quot; EBUS-EUS &quot; following a PET scan&#xD;
             showing uptake in mediastinal lymph nodes in the preoperative examination.&#xD;
&#xD;
          -  Age between 18 and 80 years&#xD;
&#xD;
          -  Patient affiliated to a social security regimen&#xD;
&#xD;
          -  Patients with a WHO performance status equal to 0 or 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults under wardship&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Tumours in contact with the pulmonary artery or developing in the lobar bronchi after&#xD;
             bronchial fibroscopy.&#xD;
&#xD;
          -  Tumours in contact with the costal periosteum or invading the chest wall&#xD;
&#xD;
          -  Tumours invading the mediastinal pleura or structures of the mediastinium (superior&#xD;
             vena cava, trachea, the main-stem bronchi, aorta, oesophagus, vertebrae)&#xD;
&#xD;
          -  Tumours invading the diaphragm&#xD;
&#xD;
          -  Tumours invading the neurovascular structures of the apex (brachial plexus,&#xD;
             subclavicular artery, subclavicular vein) causing Pancoast-Tobias syndrome&#xD;
&#xD;
          -  Patients with histologically-proven contralateral or supraclavicular lymph node (N3)&#xD;
             involvement whatever the harvesting method.&#xD;
&#xD;
          -  Patients with a positive mediastinoscopy or positive &quot;EBUS-EUS&quot; following a &quot;PET scan&quot;&#xD;
             with uptake in one or more mediastinal lymph nodes.&#xD;
&#xD;
          -  Patients with metastasis (brain, bone, liver, adrenal glands, contralateral lung,&#xD;
             pleura).&#xD;
&#xD;
          -  Patients who have undergone neo-adjuvant chemotherapy and/or radiotherapy.&#xD;
&#xD;
          -  Patients included in a neo-adjuvant chemotherapy and/or radiotherapy protocol.&#xD;
&#xD;
          -  Patients who have already undergone thoracotomy.&#xD;
&#xD;
          -  Patients with decompensated heart failure or with a systolic ejection fraction below&#xD;
             30%.&#xD;
&#xD;
          -  Patients with severe pulmonary artery hypertension.&#xD;
&#xD;
          -  Patients with untreated valve disease.&#xD;
&#xD;
          -  Patients with unstable angina despite appropriate treatment.&#xD;
&#xD;
          -  Patients with untreated carotid stenosis greater than 70%.&#xD;
&#xD;
          -  Patients with histologically proven cirrhosis with various decompensations or who have&#xD;
             presented haemoptysis because of oesophageal varicose veins.&#xD;
&#xD;
          -  Patients with severe neurological sequellae (hemiplegia, paraplegia, tetraplegia).&#xD;
&#xD;
          -  Patients presenting severe psychiatric disorders (dementia, psychosis).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alain BERNARD</last_name>
    <phone>3.80.29.33.52</phone>
    <phone_ext>+33</phone_ext>
    <email>alain.bernard@chu-dijon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aline LAUBRIET-JAZAYERI</last_name>
    <phone>03-80-28-12-94</phone>
    <phone_ext>+33</phone_ext>
    <email>aline.laubriet@chu-dijon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal BERNA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre MAGDELEINAT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Avignon</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud PFORR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin - Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc FILAIRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain BERNARD</last_name>
      <phone>380293352</phone>
      <phone_ext>+33</phone_ext>
      <email>alain.bernard@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Aline LAUBRIET-JAZAYERI</last_name>
      <phone>03-80-28-12-94</phone>
      <phone_ext>+33</phone_ext>
      <email>aline.laubriet@chu-dijon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HCL - Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel MAURY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHM Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal-Alexandre THOMAS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles MARTY-ANE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme MOUROUX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emelyne HAMELIN-CANNY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital de Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalal Assouad</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe JAYLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand DE LATOUR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe PEILLON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HUS Strasbourg - Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Emmanuel FALCOZ</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proven or suspected lung cancer treated by lobectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

